All In Biotech

Drug Trial Radar · NCT06596291

Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Jan 8, 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Cyllene TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Congressionally Directed Medical Research Programs
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), who have persistent incontinence after standard of care therapy and who perform Clear Intermittent Catheterization (CIC) on a regular basis.

Conditions

  • Neurogenic Detrusor Overactivity
  • Spinal Cord Injuries

Interventions

  • EG110ADrug

    Participants treated with EG110A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: 1 year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Rancho Los Amigos National Rehabilitation Center

    Downey, California · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Withdrawn

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Sidney Kimmel Medical College

    Philadelphia, Pennsylvania · Recruiting

  • UTHealth Houston / TIRR Memorial Hermann

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.